Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pinaverium is a spasmolytic agent primarily used for the symptomatic treatment of irritable bowel syndrome (IBS) and functional disorders of the biliary tract. It is a quaternary ammonium compound that acts as an atypical calcium antagonist, specifically blocking voltage-dependent L-type calcium channels on gastrointestinal smooth muscle cells. This inhibition reduces smooth muscle contractions in the GI tract, leading to relief from symptoms such as abdominal pain, cramping, bloating, constipation, and diarrhea. Pinaverium is not FDA-approved but is available in over 60 countries including Canada. It has minimal systemic absorption and acts locally within the gut[2][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pinaverium.